AAPS PharmSciTech

, Volume 19, Issue 3, pp 1160–1167 | Cite as

Combined Poly(Lactide-Co-Glycolide) Microspheres Containing Diphtheria Toxoid for a Single-shot Immunization

  • Hye Seung Woo
  • Sung Rae Kim
  • Mikyeong Yoon
  • Eun Seok Lee
  • In Ho Chang
  • Young Mi Whang
  • Do Ik Lee
  • Myung Joo Kang
  • Young Wook Choi
Research Article


To develop a single-shot vaccine containing diphtheria toxoid (DT) with a sufficient immune response, poly(lactide-co-glycolide) (PLGA) microspheres were prepared by water-in-oil-in-water double emulsification and solvent extraction techniques using low or high-molecular-weight PLGA (LMW-MS or HMW-MS). Stearic acid (SA) was introduced to HMW-MS (HMW/SA-MS) as a release modulator. Mean particle sizes (dvs, μm) varied between the prepared microspheres, with LMW-MS, HMW-MS, and HMW/SA-MS having the sizes of 29.83, 110.59, and 69.5 μm, respectively; however, the protein entrapment and loading efficiency did not vary, with values of 15.2–16.8 μg/mg and 61–75%, respectively. LMW-MS showed slower initial release (~ 2 weeks) but faster and higher release of antigen during weeks 3~7 than did HMW-MS. HMW/SA-MS showed rapid initial release followed by a continuous release over an extended period of time (~ 12 weeks). Mixed PLGA microspheres (MIX-MS), a combination of HMW/SA-MS and LMW-MS (1:1), demonstrated a sufficient initial antigen release and a subsequent boost release in a pulsatile manner. Serum antibody levels were measured by ELISA after DT immunization of Balb/c mice, and showed a greater response to MIX-MS than to alum-adsorbed DT (control). A lethal toxin challenge test with MIX-MS (a DT dose of 18 Lf) using Balb/c mice revealed complete protection, indicating a good candidate delivery system for a single-shot immunization.


PLGA single-shot vaccine diphtheria toxoid stearic acid immunization 


Funding Information

This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI17C0710).


  1. 1.
    Park JY, Kim MG, Shim G, Oh YK. Lipid-based antigen delivery systems. J Pharm Invest. 2016;46(4):295–304.
  2. 2.
    Saroja CH, Lakshmi PK, Bhaskaran S. Recent trends in vaccine delivery systems: a review. Int J Pharm Investig. 2011;1(2):64–74. Scholar
  3. 3.
    Drain PK, Nelson CM, Lloyd JS. Single-dose versus multi-dose vaccine vials for immunization programmes in developing countries. Bull World Health Organ. 2003;81(10):726–31.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Feng L, Qi XR, Zhou XJ, Maitani Y, Wang SC, Jiang Y, et al. Pharmaceutical and immunological evaluation of a single-dose hepatitis B vaccine using PLGA microspheres. J Control Release. 2006;112(1):35–42.Google Scholar
  5. 5.
    Johansen P, Men Y, Merkle HP, Gander B. Revisiting PLA/PLGA microspheres: an analysis of their potential in parenteral vaccination. Eur J Pharm Biopharm. 2000;50(1):129–46. Scholar
  6. 6.
    Yoon MK, Choi YW. Improved antigen delivery systems with PLGA microsphere for a single-step immunization. J Pharm Invest. 2004;34(1):1–14.
  7. 7.
    Kim JH, Choi EH, Park SE, Kim YJ, Jo DS, Kim YK, et al. Recommended immunization schedule for children and adolescents: Immunization Guideline (8th edition) released by the Korean Pediatric Society in 2015. Korean J Pediatr. 2016;59(12):461–5. Scholar
  8. 8.
    Baker CJ. Red book atlas of pediatric infectious diseases. 3rd ed. Elk Grove: American Academy of Pediatrics; 2016.Google Scholar
  9. 9.
    Siegrist CA. Vaccine immunology. In: Vaccines. 6th ed. USA: Elsevier; 2013. p. 14–32.CrossRefGoogle Scholar
  10. 10.
    Rosas JE, Pedraz JL, Hernández RM, Gascón AR, Igartua M, Guzmán F, et al. Remarkably high antibody levels and protection against P. falciparum malaria in Aotus monkeys after a single immunisation of SPf66 encapsulated in PLGA microspheres. Vaccine. 2002;20(13-14):1707–10.
  11. 11.
    Singh M, Li XM, Wang H, McGee JP, Zamb T, Koff W, et al. Immunogenicity and protection in small-animal models with controlled-release tetanus toxoid microparticles as a single-dose vaccine. Infect Immun. 1997;65(5):1716–21.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Thomasin C, Corradin G, Men Y, Merkle HP, Gander B. Tetanus toxoid and synthetic malaria antigen containing poly(lactide)/poly(lactide-co-glycolide) microspheres: importance of polymer degradation and antigen release for immune response. J Control Release. 1996;41(1–2):131–45. Scholar
  13. 13.
    Lee HK, Park JH, Kwon KC. Double-walled microparticles for single shot vaccine. J Control Release. 1997;44(2-3):283–93.
  14. 14.
    Audran R, Peter K, Dannull J, Men Y, Scandella E, Groettrup M, et al. Encapsulation of peptides in biodegradable microspheres prolongs their MHC class-I presentation by dendritic cells and macrophages in vitro. Vaccine. 2003;21(11):1250–5.
  15. 15.
    Park Ok, Yu GH, Jung HJ, Mok HJ. Recent studies on micro-/nano-sized biomaterials for cancer immunotherapy. J Pharm Invest. 2017;47(1):11–8.
  16. 16.
    Raghuvanshi RS, Katare YK, Lalwani K, Ali MM, Singh O, Panda AK. Improved immune response from biodegradable polymer particles entrapping tetanus toxoid by use of different immunization protocol and adjuvants. Int J Pharm. 2002;245(1-2):109–21.
  17. 17.
    Demento SL, Cui W, Criscione JM, Stern E, Tulipan J, Kaech SM, et al. Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype. Biomaterials. 2012;33(19):4957–64. Scholar
  18. 18.
    Kaech SM, Ahmed R. Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naïve cells. Nat Immunol. 2001;2(5):415–22. Scholar
  19. 19.
    Jeffery H, Davis SS, O’Hagan DT. The preparation and characterization of poly(lactide-co-glycolide) microparticles. II. The entrapment of a model protein using a (water-in-oil)-in-water emulsion solvent evaporation technique. Pharm Res. 1993;10(3):362–8. Scholar
  20. 20.
    Al-Maaieh A, Flanagan DR. Salt and cosolvent effects on ionic drug loading into microspheres using an O/W method. J Control Release. 2001;70(1-2):169–81. Scholar
  21. 21.
    O’Hagan DT, Jeffery H, Davis SS. The preparation and characterization of poly (lactide-co-glycolide) microspheres: III. Microparticle/polymer degradation rates and the in vitro release of a model protein. Int J Pharm. 1994;103(1):37–45. Scholar
  22. 22.
    Matsuo K, Ishii Y, Quan YS, Kamiyama F, Mukai Y, Yoshioka Y, et al. Transcutaneous vaccination using a hydrogel patch induces effective immune responses to tetanus and diphtheria toxoid in hairless rat. J Control Release. 2011;149(1):15–20. Scholar
  23. 23.
    Uchida T, Martin S, Foster TP, Wardley RC, Grimm S. Dose and load studies for subcutaneous and oral delivery of poly (lactide-co-glycolide) microspheres containing ovalbumin. Pharm Res. 1994;11(7):1009–15. Scholar
  24. 24.
    Jung T, Koneberg R, Hungerer KD, Kissel T. Tetanus toxoid microspheres consisting of biodegradable poly(lactide-co-glycolide)- and ABA-triblock-copolymers: immune response in mice. Int J Pharm. 2002;234(1-2):75–90.
  25. 25.
    Desai KGH, Schwendeman SP. Active self-healing encapsulation of vaccine antigens in PLGA microspheres. J Control Release. 2013;165(1):62–74. Scholar
  26. 26.
    Jiang W, Gupta RK, Deshpande MC, Schwendeman SP. Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. Adv Drug Deliv Rev. 2005;57(3):391–410. Scholar
  27. 27.
    Yeo Y, Park K. Control of encapsulation efficiency and initial burst in polymeric microparticle systems. Arch Pharm Res. 2004;27(1):1–12. Scholar
  28. 28.
    Yang YY, Chung TS, Ng NP. Morphology, drug distribution and in vitro release profiles of biodegradable polymeric microspheres containing protein fabricated by double-emulsion solvent extraction/evaporation method. Biomaterials. 2001;22(3):231–41. Scholar
  29. 29.
    Reits E, Griekspoor A, Neijssen J, Groothuis T, Jalink K, van Veelen P, et al. Peptide diffusion, protection, and degradation in nuclear and cytoplasmic compartments before antigen presentation by MHC class I. Immunity. 2003;18(1):97–108. Scholar
  30. 30.
    Huang X, Brazel CS. On the importance and mechanisms of burst release in matrix-controlled drug delivery systems. J Control Release. 2001;73(2-3):121–36.
  31. 31.
    Hausberger AG, DeLuca PP. Characterization of biodegradable poly (D, L-lactide-co-glycolide) polymers and microspheres. J Pharm Biomed Anal. 1995;13(6):747–60. Scholar
  32. 32.
    Passerini N, Craig DQM. An investigation into the effects of residual water on the glass transition temperature of polylactide microspheres using modulated temperature DSC. J Control Release. 2001;73(1):111–5. Scholar
  33. 33.
    Kim HS, Shin TH, Yoon MK, Kang MJ, Lee JH, Choi YW. Effects of non-ionic surfactant on the release of protein drug from poly (dl-lactide-co-glycolide) microspheres. Tissue Eng Regen Med. 2008;5(4):798–803.Google Scholar
  34. 34.
    Singh M, Kazzaz J, Ugozzoli M, Malyala P, Chesko J, O’Hagan DT. Polylactide-co-glycolide microparticles with surface adsorbed antigens as vaccine delivery systems. Curr Drug Deliv. 2006;3(1):115–20. Scholar
  35. 35.
    Qiu S, Wei Q, Liang Z, Ma G, Wang L, An W, et al. Biodegradable polylactide microspheres enhance specific immune response induced by Hepatitis B surface antigen. Hum Vaccin Immunother. 2014;10(8):2350–6. Scholar
  36. 36.
    Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol. 2010;10(11):787–96. Scholar
  37. 37.
    Wu F, Jin T. Polymer-based sustained-release dosage forms for protein drugs, challenges, and recent advances. AAPS PharmSciTech. 2008;9(4):1218–29. Scholar
  38. 38.
    Chu D, Tian J, Liu W, Li Z, Li Y. Poly(lactic-co-glycolic acid) microspheres for the controlled release of huperzine a: in vitro and in vivo studies and the application in the treatment of the impaired memory of mice. Chem Pharm Bull. 2007;55(4):625–8.
  39. 39.
    Kissel T, Li YX, Volland C, Gorich S, Koneberg R. Parenteral protein delivery systems using biodegradable polyesters of ABA block structure, containing hydrophobic poly(lactide-co-glycolide) A blocks and hydrophilic poly(ethylene oxide) B blocks. J Control Release. 2006;39(2-3):315–26.Google Scholar
  40. 40.
    Cleland JL. Single-administration vaccines: controlled-release technology to mimic repeated immunizations. Trends Biotechnol. 1999;17(1):25–9. Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2017

Authors and Affiliations

  • Hye Seung Woo
    • 1
  • Sung Rae Kim
    • 1
  • Mikyeong Yoon
    • 1
  • Eun Seok Lee
    • 1
  • In Ho Chang
    • 2
  • Young Mi Whang
    • 2
  • Do Ik Lee
    • 1
  • Myung Joo Kang
    • 3
  • Young Wook Choi
    • 1
  1. 1.College of PharmacyChung-Ang UniversitySeoulSouth Korea
  2. 2.Colleg of MedicineChung-Ang UniversitySeoulSouth Korea
  3. 3.College of PharmacyDankook UniversityCheonanSouth Korea

Personalised recommendations